Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
PMT PennyMac Mortgage Investment Trust
GS Goldman Sachs Group Inc
HLBZ Helbiz Inc
SRNE Sorrento Therapeutics Inc
OKTA Okta Inc
AAPL Apple Inc
CBTTF Cathedra Bitcoin Inc
IPVF InterPrivate III Financial Partners Inc
MFD Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Postmarket

Last Trade
Delayed
$124.96
-0.64 (-0.51%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$125.60
Day's Change
-1.15 (-0.91%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
129.06
Day's Low
125.02
Volume
(Light)
Volume:
330,301

10-day average volume:
838,866
330,301

Display:

Providers:

UpdateCancel
6 providers
May 24, 2022
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

--- Expands Upon Previously Reported Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from the...(BusinessWire)

May 23, 2022
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran

--- Improvements in NT-proBNP and Echocardiographic Parameters Seen in Cardiac Subpopulation - --- Reductions in Technetium Uptake Observed in Patients with High Grade Uptake at Baseline - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading...(BusinessWire)

May 04, 2022
Alnylam to Webcast Presentations at Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022...(BusinessWire)

April 28, 2022
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

--a^' Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy - --a^' Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due to Amendment to...(BusinessWire)

April 14, 2022
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2022 on Thursday, April 28, 2022, before the U.S. financial markets...(BusinessWire)

April 05, 2022
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective April 16, 2022. Dr. Paul has served as a member of the Alnylam Board of Directors...(BusinessWire)

April 04, 2022
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

--- New facility has been identified and incorporated into existing regulatory submission which requires additional review time at FDA - --- No inspection observations were directly related to vutrisiran and no additional clinical data have been...(BusinessWire)

March 22, 2022
Alnylam to Webcast Presentation at Stifel 2022 CNS Days

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET (BusinessWire)

March 17, 2022
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking...(BusinessWire)

March 16, 2022
Alnylam Issues 2021 Corporate Responsibility Report

--- Aligns with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) Reporting Frameworks - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2021 Corporate...(BusinessWire)

March 01, 2022
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO(R) for the Treatment of Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) for lumasiran, an...(BusinessWire)

February 28, 2022
Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022 at...(BusinessWire)

Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)

--- Viewers Encouraged to "Tell 15" People about Film to Shorten the 15 Years It Can Take to Diagnose AHP - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today on Rare Disease Day announced the premiere of its...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.